AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16883914
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment (control)
Trial: 8828744
Drug: Higher-dose didanosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-dose didanosine (750 mg per day for patients > or = 60 kg)
Trial: 8828744
Drug: Lower-dose didanosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-dose didanosine (200 mg per day)
Trial: 8828744
Drug: Higher-dose didanosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-dose didanosine
Trial: 8828744
Drug: Lower-dose didanosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-dose didanosine
Trial: 27138022
Drug: Single-dose study
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose study
Trial: 27138022
Drug: Multiple-dose study
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multiple-dose study
Trial: 3544186
Drug: Pirenzepine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine (10 mg)
Trial: 3933861
Drug: Pirenzepine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine (30 mg)
Trial: 3933861
Drug: Pirenzepine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine (40 mg)
Trial: 31223014
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment method from 2000-2005
Trial: 28028723
Drug: Shenfu Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenfu Injection (SFI) treatment (100 mL/24 h)
Trial: 25576680
Drug: <2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: <2 g sodium diet education
Trial: 25576680
Drug: <2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: <2 g sodium diet education (2 samples)
Trial: 23364361
Drug: Sedative instrumental
RxNorm normalized name: MedActive Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sedative instrumental music (60-80 beats per minute)
Trial: 9416888
Drug: Lisinopril (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (2.5 to 5 up to 10 mg/d) with or without nitroglycerin (5 to 20 microg I.V. then 10 mg/d)
Trial: 8269890
Drug: Vegan diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vegan diet (uncooked 'living food') for 3 months, tutored daily by a living-food expert.
Trial: 3114203
Drug: Gonadotropin-releasing hormone
RxNorm normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gonadotropin-releasing hormone (GnRH) 500 micrograms
Trial: 23671022
Drug: Coffee 6
RxNorm normalized name: Coffee, green
DrugBank: Arabica coffee bean (DB10666)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coffee 6 (6 mg caffeine/kg body weight)
Trial: 23671022
Drug: Coffee 3
RxNorm normalized name: Coffee, green
DrugBank: Arabica coffee bean (DB10666)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coffee 3 (3 mg caffeine/kg body weight)
Trial: 19131132
Drug: G‐CSF (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF (10 microg/kg/day)
Trial: 16893641
Drug: Preoperative concurrent
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative concurrent chemoradiotherapy (5‐fluorouracil (5‐FU) 500 mg/m2/d continuous infusion for 4 cycles and vinorelbine 25 mg/m2 on specific days)
Trial: 16893641
Drug: Preoperative concurrent
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative concurrent chemoradiotherapy
Trial: 11293237
Drug: Pamidronate 60
RxNorm normalized name: pamidronate 60 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate 60 mg i.v. monthly
Trial: 8864319
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate 800 mg given twice daily for 28 days
Trial: 1735313
Drug: PSK (oral)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSK (oral) for over three years, mitomycin C intravenously on the day of and the day after surgery, followed by oral 5-fluorouracil (5-FU) for over six months.
Trial: 1735313
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C intravenously on the day of and the day after surgery, followed by oral 5-fluorouracil (5-FU) for over six months.
Trial: 6122188
Drug: Lorazepam (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (3.0 mg)
Trial: 30420479
Drug: Dolutegravir (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir (50 mg once daily) with artemether-lumefantrine
Trial: 30420479
Drug: Dolutegravir (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir (50 mg once daily) with artesunate-amodiaquine
Trial: 26966119
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg of DAR-0100A
Trial: 26966119
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg of DAR-0100A
Trial: 11722957
Drug: Excess dietary
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Excess dietary cysteine (21 mg x kg(‐1) x d(‐1))
Trial: 9135425
Drug: Textured silicone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Textured silicone gel-filled implants
Trial: 9135425
Drug: Smooth silicone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smooth silicone gel-filled implants
Trial: 8189476
Drug: rhGH (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH (0.15 mg/kg/day, Somatropin, Genentech, Inc.)
Trial: 3555687
Drug: Single-dose cefotaxime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose cefotaxime
Trial: 3555687
Drug: Single-dose cephradine
RxNorm normalized name: Cephradine
DrugBank: Cefradine (DB01333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose cephradine
Trial: 31297582
Drug: Topical steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical steroids (Group T, n: 42)
Trial: 31297582
Drug: Systemic steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic steroids (0.8 mg/kg/day peroral, Group S, n: 42)
Trial: 31297582
Drug: Combined steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined steroids (0.4 mg/kg/day peroral + topical, Group C, n: 40)
Trial: 28891198
Drug: Targeted medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted medical nutrition (TMN) - 230 kcal; 2 g omega-3 fatty acids; 10 μg 25-hydroxy-vitamin D3, administered twice daily for 12 weeks.
Trial: 28891198
Drug: Isocaloric comparator,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isocaloric comparator, administered twice daily for 12 weeks.
Trial: 28273329
Drug: Paper mode
RxNorm normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paper mode of administration
Trial: 28273329
Drug: Electronic mode
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic mode of administration
Trial: 28273329
Drug: Mixed-mode administration
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed-mode administration
Trial: 25354927
Drug: Web-based behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based behavioral activation intervention (Bounce Back Now); specific dosage and duration not mentioned.
Trial: 22490629
Drug: Intensive antiplatelet
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive antiplatelet therapy (double maintenance dose of clopidogrel 150 mg/d and aspirin 300 mg/d, followed by cilostazol 50-100 mg bid if HPR persists)
Trial: 22490629
Drug: Standard antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antiplatelet therapy (aspirin 300 mg/d and clopidogrel 75 mg/d)
Trial: 17697904
Drug: LID 40
RxNorm normalized name: linezolid 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LID 40 mg + MET 5 mg
Trial: 17697904
Drug: LID 40
RxNorm normalized name: linezolid 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LID 40 mg + MET 10 mg
Trial: 17697904
Drug: LID 40
RxNorm normalized name: linezolid 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LID 40 mg + MET 2.5 mg
Trial: 1693007
Drug: Dakin solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dakin solution after 15 days of inefficacy of previous antiseptics
Trial: 7281085
Drug: Radiotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy with chemotherapy (adriamycin and 5-fluorouracil)
Trial: 23252583
Drug: Piroxicam +
RxNorm normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Piroxicam + Low-level laser therapy
Trial: 15377583
Drug: Esmolol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol (0.5 mg kg(‐1) loading dose followed by 0.05 mg kg(‐1) min(‐1) infusion)
Trial: 8026260
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg twice a day plus amoxicillin 1 g twice a day (group I, N = 30)
Trial: 8026260
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg twice a day plus amoxicillin 1 g twice a day (group II, N = 30)
Trial: 8026260
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg twice a day plus amoxicillin 1 g three times a day (group III, N = 30)
Trial: 2574836
Drug: Atracurium (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium (initial bolus 0.5 mg/kg, continuous infusion 5.5 micrograms/kg/min)
Trial: 2574836
Drug: Vecuronium (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium (initial bolus 0.08 mg/kg, continuous infusion 0.9 micrograms/kg/min)
Trial: 2574836
Drug: Atracurium with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium with prostigmin (0.04 mg/kg) in recovery phase
Trial: 2574836
Drug: Vecuronium with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium with prostigmin (0.04 mg/kg) in recovery phase
Trial: 31996926
Drug: High-volume hemofiltration
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-volume hemofiltration continuous renal replacement therapy
Trial: 28215362
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg sirukumab every 4 weeks
Trial: 28215362
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg sirukumab every 2 weeks
Trial: 18452749
Drug: Motor point
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motor point injection technique with 60U of BTX‐A (Botox) in 2.4mL or 30U BTX‐A in 1.2mL of saline
Trial: 18452749
Drug: Multisite distributed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multisite distributed injection technique with 90U of BTX‐A in 3.6mL
Trial: 12698647
Drug: Postoperative intravenous
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative intravenous injection of Irinotekan (group 1)
Trial: 12698647
Drug: Intraarterial regional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarterial regional injection of Irinotekan (group 2)
Trial: 12698647
Drug: Intraarterial therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarterial therapy with Irinotekan (group 3)
Trial: 12698647
Drug: Systemic intravenous
RxNorm normalized name: Vaginal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic intravenous therapy with Irinotekan (group 4)
Trial: 10886044
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg as simplified omeprazole suspension
Trial: 10886044
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg as simplified lansoprazole suspension
Trial: 10886044
Drug: Omeprazole capsules
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole capsules
Trial: 10886044
Drug: Lansoprazole capsules
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole capsules
Trial: 9298736
Drug: Interferon alpha-2a,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alpha-2a, 9 megaunits thrice weekly for six months
Trial: 8373935
Drug: Aspartame 30
RxNorm normalized name: Aspartame
DrugBank: Aspartame (DB00168)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspartame 30 mg/kg/day
Trial: 3780838
Drug: Torasemide 20
RxNorm normalized name: Torasemide 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torasemide 20 mg and Furosemide 40 mg
Trial: 31005204
Drug: Xelac: concomitant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xelac: concomitant boost to bulky site (45 Gy/1.8 Gy/day, 5 sessions/week to the pelvis, +10 Gy at 1 Gy twice/week to the bulky) plus concurrent capecitabine (1650 mg/mq/day)
Trial: 31005204
Drug: Xelox: 45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xelox: 45 Gy to the pelvis + 5.4 Gy/1.8 Gy/day, 5 sessions/week to the bulky site + concurrent capecitabine (1300 mg/mq/day) and oxaliplatin (130 mg/mq on days 1, 19, 38)
Trial: 12636463
Drug: Less than
RxNorm normalized name: IgA less than or equal to 50 mcg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less than 1 drink weekly
Trial: 12636463
Drug: 1 to
RxNorm normalized name: Cep-11981 tosylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 to 6 drinks weekly
Trial: 12636463
Drug: 7 to
RxNorm normalized name: NP-27 Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 to 13 drinks weekly
Trial: 12636463
Drug: 14 or
RxNorm normalized name: LACTOBACILLUS 14/14 ORAL & VAG CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 or more drinks weekly
Trial: 8794786
Drug: Tetraprenylacetone (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetraprenylacetone (300 mg for four weeks)
Trial: 1523076
Drug: Ceftibuten (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftibuten (5 days treatment)
Trial: 1523076
Drug: Trimethoprim-sulfamethoxazole (TMP-SMX)
RxNorm normalized name: sulfamethoxazole / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMX) (5 days treatment)
Trial: 1523076
Drug: Ceftibuten and
RxNorm normalized name: Ceftibuten
DrugBank: Ceftibuten (DB01415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftibuten and TMP-SMX (both treatments)
Trial: 6823418
Drug: Human milk
RxNorm normalized name: HUMAN MILK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human milk (185 mL/kg/d)
Trial: 26720597
Drug: Tolterodine ER
RxNorm normalized name: tolterodine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine ER 4 mg/day for 8 weeks
Trial: 22424722
Drug: Nevirapine-based treatment
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nevirapine-based treatment after suppression with protease-inhibitor-based regimen
Trial: 22424722
Drug: Protease-inhibitor-based treatment
RxNorm normalized name: Protease inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease-inhibitor-based treatment (ritonavir-boosted lopinavir)
Trial: 20121419
Drug: Efavirenz therapy
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Efavirenz therapy
Trial: 10875030
Drug: Dofetilide (15-min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dofetilide (15-min loading infusion of 4 g/kg followed by a 60-min maintenance infusion of 3.5 g/kg, total dose of 7.5 g/kg)
Trial: 10875030
Drug: Placebo (single-blind
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (single-blind infusion)
Trial: 8741938
Drug: Diazepam (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (4 mg)
Trial: 8741938
Drug: Buspirone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (5 mg)
Trial: 8428895
Drug: triazolam 0.5
RxNorm normalized name: triazolam 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: triazolam 0.5 mg
Trial: 6145178
Drug: withdrawal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: withdrawal of either drug after 3 weeks
Trial: 30398602
Drug: Inhaled inorganic
RxNorm normalized name: Organic germanium
DrugBank: Propagermanium (DB17608)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled inorganic nitrite (46 mg 3 times a day for 1 week followed by 80 mg 3 times a day for 3 weeks)
Trial: 28476756
Drug: Inhaled inorganic
RxNorm normalized name: Organic germanium
DrugBank: Propagermanium (DB17608)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled inorganic nitrite
Trial: 22575544
Drug: 200 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 μg I (as KI) daily throughout pregnancy
Trial: 19092246
Drug: Low-dose propofol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose propofol (40 mg for <70 years, 30 mg for ≥70 years)
Trial: 19092246
Drug: Low-dose propofol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose propofol vs. Midazolam
Trial: 12360457
Drug: Budesonide 9
RxNorm normalized name: budesonide 9 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 9 mg/day for 6 weeks
Trial: 28857147
Drug: Aminophylline (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline (500 mg)
Trial: 8970501
Drug: Valproate (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valproate (oral loading dosage)
Trial: 8970501
Drug: Carbamazepine and
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbamazepine and lithium (combination treatment)
Trial: 6433770
Drug: HB 419
RxNorm normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HB 419 (5 mg twice a day)
Trial: 6433770
Drug: HB 420
RxNorm normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HB 420 (3.5 mg twice a day)
Trial: 26954726
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of female emotional tears
Trial: 26545199
Drug: 1,25(OH)2D3 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,25(OH)2D3 (2 μg daily for 7 days)
Trial: 19716512
Drug: Immediate post
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate post space preparation using heated instrument (Group A)
Trial: 19716512
Drug: Delayed post
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed post space preparation after 1 week with Gates‐Glidden drills (Group B)
Trial: 9273186
Drug: CEBI 140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEBI 140 trial: Combination of daily cisplatin (6 mg/m2 per day, total 144 mg/m2), vindesine (2.5 mg/m2 once a week, total 15 mg/m2), bifractionated radiotherapy (60 Gy/48 fractions/6 weeks) followed by two cycles of cisplatin (120 mg/m2) and three cycles of vindesine (6 mg/m2).
Trial: 9273186
Drug: CEBI 142
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEBI 142 trial: Combination of cisplatin (100 mg/m2 at d1 and d24, total 200 mg/m2), vinblastine (4 mg/m2 at d1 and d24, total 8 mg/m2), 5-fluorouracil (1,000 mg/m2 from d1 to d3 and from d24 to d26, total 6,000 mg/m2), bifractionated radiotherapy (two series of 21 Gy/14 fractions/9 days, 11 days apart) followed by surgical excision.
Trial: 26845098
Drug: 300,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300,000 IU of cholecalciferol administered 4 days before surgery
Trial: 26845098
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered during the first extraction (control group)
Trial: 19583756
Drug: Five sessions
RxNorm normalized name: Alternanthera sessilis extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five sessions of cognitive behavioural therapy (CBT) performed by dentists
Trial: 19583756
Drug: One session
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One session of cognitive behavioural therapy (CBT) performed by dentists
Trial: 16960445
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy with bisoprolol
Trial: 16960445
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy with placebo
Trial: 16960445
Drug: No statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No statin therapy with bisoprolol
Trial: 16960445
Drug: No statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No statin therapy with placebo
Trial: 16960445
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy (both with bisoprolol and placebo)
Trial: 11476119
Drug: Risperidone (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (up to 10 mg/day)
Trial: 11476119
Drug: Haloperidol (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (up to 20 mg/day)